- Trials with a EudraCT protocol (1,321)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (3)
1,321 result(s) found for: serbia.
Displaying page 1 of 67.
| EudraCT Number: 2014-004659-30 | Sponsor Protocol Number: PKM6270 | Start Date*: 2015-03-17 |
| Sponsor Name:sanofi-aventis | ||
| Full Title: Four-week, open-label, multicenter, randomized, parallel-group study to investigate the pharmacokinetics, safety, tolerability and the effects on leak point pressure of 2 oral doses of alfuzosin (0... | ||
| Medical condition: Urinary Bladder Neurogenic | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2019-003625-16 | Sponsor Protocol Number: TG1101-RMS303 | Start Date*: 2020-04-15 | |||||||||||
| Sponsor Name:TG Therapeutics, Inc. | |||||||||||||
| Full Title: An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis | |||||||||||||
| Medical condition: Relapsing Multiple Sclerosis | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: PL (Trial now transitioned) HR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2013-005159-34 | Sponsor Protocol Number: IG1103 | Start Date*: 2014-06-16 |
| Sponsor Name:Instituto Grifols, S.A. | ||
| Full Title: A Prospective, Single-blind, Randomized, Phase III Study to Evaluate the Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) as an Adjunct to Hemostasis During Soft Tissue Open Surgeries | ||
| Medical condition: Treatment of haemorrhage resulting from soft tissue surgical procedure | ||
| Disease: | ||
| Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
| Trial protocol: HU (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2011-000091-33 | Sponsor Protocol Number: 2125-203 | Start Date*: 2011-04-08 |
| Sponsor Name:Idera Pharmaceuticals, Inc. | ||
| Full Title: A Phase 2, Randomized, Double-Blind, Comparator-Controlled, 12-week Trial of IMO-2125 plus Ribavirin in Treatment-Naive Patients Infected with Hepatitis C Virus, Genotype 1 | ||
| Medical condition: Treatment-Naive Patients Infected with Hepatitis C Virus Genotype 1. | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: HU (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2013-005127-16 | Sponsor Protocol Number: IG1101 | Start Date*: 2014-06-16 |
| Sponsor Name:Instituto Grifols, S.A. | ||
| Full Title: A Prospective, Single-blind, Randomized, Phase III Study to Evaluate the Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) as an Adjunct to Hemostasis during Peripheral Vascular Surgery | ||
| Medical condition: Treatment of haemorrhage resulting from a vascular surgical procedure | ||
| Disease: | ||
| Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
| Trial protocol: HU (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2016-005199-90 | Sponsor Protocol Number: RHB-104-04 | Start Date*: 2019-02-14 | |||||||||||
| Sponsor Name:RedHill Biopharma Ltd. | |||||||||||||
| Full Title: An Open Label Study to Assess the Efficacy and Safety of Fixed-Dose Combination RHB-104 in Subjects with Active Crohn’s Disease Despite 26 Weeks of Participation in the MAP US RHB-104-01 Study | |||||||||||||
| Medical condition: Moderately to Severely Active Crohn's Disease | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SK (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-005138-21 | Sponsor Protocol Number: TC-5619-23-CRD-003 | Start Date*: 2012-04-03 |
| Sponsor Name:Targacept Inc. | ||
| Full Title: A double-blind, placebo-controlled, multicenter, parallel group study to assess efficacy, safety and tolerability of TC-5619 as augmentation therapy to improve negative symptoms and cognition in ou... | ||
| Medical condition: Schizophrenia | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: HU (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2013-005128-40 | Sponsor Protocol Number: IG1102 | Start Date*: 2014-06-16 |
| Sponsor Name:Instituto Grifols, S.A. | ||
| Full Title: A Prospective, Single-blind, Randomized, Phase III Study to Evaluate the Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) as an Adjunct to Hemostasis During Parenchymous Tissue Open Surge... | ||
| Medical condition: Treatment of haemorrhage resulting from parenchymous tissue surgical procedure | ||
| Disease: | ||
| Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
| Trial protocol: HU (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2014-003737-26 | Sponsor Protocol Number: A3191342 | Start Date*: 2015-04-07 |
| Sponsor Name:Pfizer Inc | ||
| Full Title: A Phase 4, 6-week, randomized double-blind, multicenter, active-controlled trial to evaluate the effects of Celecoxib (Celebrex®) or Naproxen on blood pressure in paediatric subjects with juvenile ... | ||
| Medical condition: Juvenile idiopathic arthritis | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2015-001919-13 | Sponsor Protocol Number: NN1731-4214 | Start Date*: 2016-03-17 | ||||||||||||||||
| Sponsor Name:Novo Nordisk A/S | ||||||||||||||||||
| Full Title: Pharmacogenetic testing of saliva samples from patients with ≥5 exposure days to rFVIIa analogue in the adept™2 trial. Bio-specimen research study | ||||||||||||||||||
| Medical condition: - Haemophilia A with inhibitors - Haemophilia B with inhibitors | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adolescents, Under 18, Adults | Gender: Male | |||||||||||||||||
| Trial protocol: RO (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2013-002210-12 | Sponsor Protocol Number: COMPLETE-2013-05-01 | Start Date*: 2014-12-17 |
| Sponsor Name:Population Health Research Institute | ||
| Full Title: A randomized, comparative effectiveness study of complete versus culprit-only revascularization strategies to treat multi-vessel disease after primary percutaneous coronary intervention for ST-segm... | ||
| Medical condition: Effectiveness study of complete versus culprit-only revascularization strategies to treat multi vessel disease after primary PCI for STEMI | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2018-002590-22 | Sponsor Protocol Number: NN9924-4338 | Start Date*: 2019-07-25 | |||||||||||
| Sponsor Name:Novo Nordisk A/S | |||||||||||||
| Full Title: China multi-regional clinical trial: Efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes mellitus treated with diet and exercise only | |||||||||||||
| Medical condition: Diabetes Mellitus, Type 2 | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: HU (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2018-002926-22 | Sponsor Protocol Number: ANAM-17-20 | Start Date*: 2019-04-15 |
| Sponsor Name:Helsinn Healthcare SA | ||
| Full Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia i... | ||
| Medical condition: Treatment of malignancy associated weight loss or anorexia in patients with NSCLC | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: HU (Completed) BG (Completed) IT (Completed) RO (Ongoing) | ||
| Trial results: View results | ||
| EudraCT Number: 2022-002140-51 | Sponsor Protocol Number: INV-CL-106 | Start Date*: 2022-12-21 | |||||||||||
| Sponsor Name:Inversago Pharma Inc. | |||||||||||||
| Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of Two Doses of INV-202 in Patients with Diabetic Kidney Disease | |||||||||||||
| Medical condition: Diabetic Kidney Disease | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: HU (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-006291-16 | Sponsor Protocol Number: ARC-21 | Start Date*: 2022-05-24 |
| Sponsor Name:Arcus Biosciences, Inc. | ||
| Full Title: A Phase 2 Trial to Evaluate the Safety and Efficacy of Combination Therapies in Patients with Advanced Upper Gastrointestinal Tract Malignancies (EDGE-Gastric) | ||
| Medical condition: Advanced Upper Gastrointestinal Tract Malignancies | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: FR (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2014-002386-30 | Sponsor Protocol Number: 33-04 | Start Date*: 2015-02-20 | |||||||||||
| Sponsor Name:Verein für Krebsforschung | |||||||||||||
| Full Title: Efficacy and Safety of Mistletoe Extract in the Palliative Therapy of Patients Suffering from Pancreatic Cancer (PALM-Pan) | |||||||||||||
| Medical condition: Locally advanced or metastatic adenocarcinoma of the pancreas (UICC stadium III or IV) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BG (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-005271-14 | Sponsor Protocol Number: D1050303 | Start Date*: 2013-05-06 | |||||||||||
| Sponsor Name:Sunovion Pharmaceuticals Inc | |||||||||||||
| Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LOW-DOSE LURASIDONE IN ACUTELY PSYCHOTIC SUBJECTS WITH SCHIZOPHRENIA | |||||||||||||
| Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SK (Completed) RO (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-001649-38 | Sponsor Protocol Number: 19379A | Start Date*: 2022-06-24 | |||||||||||
| Sponsor Name:H. Lundbeck A/S | |||||||||||||
| Full Title: Long-term, open-label (dose-blinded), extension study of eptinezumab in children and adolescents with chronic or episodic migraine | |||||||||||||
| Medical condition: Migraine | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) PT (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-003772-14 | Sponsor Protocol Number: GN43271 | Start Date*: 2021-11-18 | ||||||||||||||||
| Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||
| Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO INVESTIGATE THE EFFICACY OF FENEBRUTINIB IN RELAPSING MULTIPLE SCLEROSIS | ||||||||||||||||||
| Medical condition: Relapsing Multiple Sclerosis | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | |||||||||||||||||
| Trial protocol: CZ (Trial now transitioned) SK (Trial now transitioned) HR (Trial now transitioned) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2014-002839-33 | Sponsor Protocol Number: C1-3201 | Start Date*: 2015-07-09 | |||||||||||
| Sponsor Name:Pharming Group NV | |||||||||||||
| Full Title: A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, 3-Period Crossover Study to Evaluate the Efficacy and Safety of Recombinant Human C1 Inhibitor in the Prophylaxis of Angioedema ... | |||||||||||||
| Medical condition: Prophylaxis of Angioedema Attacks on Patients with Hereditary Angioedema (HAE) | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.